EUVIMEDEUVIMED entdecken
Crossref

Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation

Sara Redondo iD, Irene García-Cadenas iD, Albert Esquirol iD, J M Portos, Eva Iranzo, Miguel Arguello-Tomas, Silvana Saavedra, Guadalupe Oñate, Ana-Carolina Caballero, Ana Garrido, Jordi López, Ana Muntañola und 5 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Sara Redondo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Barcelona, Spain. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Methotrexate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Catalan Government, Barcelona, Spain, Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This retrospective single center study aims to describe changes in the severity and organ‐specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.

Methods

Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA‐matched or 1‐allele mismatched related or unrelated donors. Fifty‐eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort‐1), 87 (38%) tacrolimus plus sirolimus (Cohort‐2), and 81 (36%) post‐transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort‐3).

Results

The incidence of grade II‐IV aGvHD was 69% vs. 41.4% vs. 27.2%; p < .01. The most significant reduction with PTCy was observed in both stage 3–4 skin and lower gastrointestinal (GI) involvement ( p < .01). The incidence of moderate‐to‐severe cGvHD at 12 months was 34.5% vs. 34.5% vs. 6.2%; p < .01. Moderate‐to‐severe skin and GI cGvHD was less common after PTCy ( p < .01). The 1‐year GvHD‐free/relapse‐free survival was higher with PTCy ( p < .01).

Conclusions

Our study indicates that PTCy‐based GvHD prophylaxis reduces the frequency and severity of both acute and chronic GvHD, with a notable decrease in severe GI and cutaneous manifestations. The higher GRFS may result in lower GvHD‐related mortality, leading to an improved quality of life among survivors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationCyclophosphamideMethotrexateMycophenolic AcidSirolimusCalcineurin InhibitorsSeverity of Illness IndexTransplantation, HomologousHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedImmunosuppressive AgentsYoung AdultAdolescentHLA AntigensAllelesIncidenceOrgan SpecificityHistocompatibility TestingTransplantation ConditioningTreatment OutcomeHistocompatibility

Stichwörter der Autor:innen

GvHDallogeneic hematopoietic cell transplantnon‐relapse mortalitypost‐transplant cyclophosphamide

Substanzen

CyclophosphamideMethotrexateMycophenolic AcidSirolimusCalcineurin InhibitorsImmunosuppressive AgentsHLA Antigens

Autor:innen und Institutionen

  • Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and José Carreras Leukemia Research Institutes, Barcelona, Spain.
  • Departamento de Medicina, Universidad Autónoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Sara Redondo, Irene García-Cadenas, Albert Esquirol

Förderung

  • Catalan Government, Barcelona, Spain
  • Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain
  • Instituto de Salud Carlos III

Zitieren

APA

Redondo, S., García-Cadenas, I., Esquirol, A., Portos, J. M., Iranzo, E., Arguello-Tomas, M., Saavedra, S., Oñate, G., Caballero, A. C., Garrido, A., López, J., Muntañola, A., Paviglianiti, A., Miqueleiz, S., Sierra, J., Briones, J., & Martino, R. (2024). Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation. European Journal of Haematology. https://doi.org/10.1111/ejh.14294

Vancouver

Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, et al. Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation. European Journal of Haematology. 2024. doi:10.1111/ejh.14294

BibTeX
@article{Redondo2024,
  author = {Redondo, Sara and García-Cadenas, Irene and Esquirol, Albert and Portos, J M and Iranzo, Eva and Arguello-Tomas, Miguel and Saavedra, Silvana and Oñate, Guadalupe and Caballero, Ana-Carolina and Garrido, Ana and López, Jordi and Muntañola, Ana and Paviglianiti, Annalisa and Miqueleiz, Sara and Sierra, Jorge and Briones, Javier and Martino, Rodrigo},
  title = {Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14294}
}
Kostenlos starten →